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Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML
is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML
express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR)
generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical
translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even
without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in
chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the
achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after
5 months transformed into lymphoid blast crisis.
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Chronic myelogenous leukemia (CML) results from the
neoplastic transformation of a hematopoietic stem cell.
This leukemia is cytogenetically characterized by the
presence of the Philadelphia chromosome (Ph’), which
results from the reciprocal translocation t(9;22) (q34;
q11) that juxtaposes the c-abl oncogene 1 (ABL1) gene
on chromosome 9 with the breakpoint cluster region
(BCR) gene on chromosome 22 generating the BCR-
ABL1 oncogene [1-3]. The BCR-ABL fusion protein is
the product of the Philadelphia chromosome [4].
Depending on the location of the breakpoint in BCR,
several types of BCR-ABL fusion protein may be formed
[5]. To date 3 main breakpoint cluster regions in the
BCR gene have been reported: The M-bcr region located
between exons 12 and 16, the m-bcr located between
exons e2′ and e2 and the u-bcr located in exon 19 [5-7].* Correspondence: jorgej.martinez@ssib.es
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article, unless otherwise stated.The point of rupture in the ABL gene usually occurs in
exon 2 (a2). Most patients with CML express e13a2 or
e14a2 mRNAs that result from a rearrangement of the
major breakpoint cluster regions (M-BCR) generating
the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or
b3a2 respectively, mainly associated to CML. Another
typical breakpoint within the BCR occurs in exons 1 (e1)
and 19 (e19) generating the rearrangements e1a2
(p190BCR-ABL) or e19a2 (p230BCR-ABL), associated to
acute lymphoblastic leukemia (ALL) or neutrophil CML,
respectively [5-8]. The type of rearrangement in CML is
thought to be related to the patient clinical course. Here
we report a CML case with the rare e1a3 translocation.
One of the main features of this type of translocation is
the absence of the exon a2, normally present in the
other translocations. The e1a3 BCR-ABL1 related CML
has been reported with an indolent clinical course, low
leukocyte count, long chronic phase even without treat-
ment and good response to therapy [9,10]. The abl exon
a2 sequence, code for a part of the SH3 region of the abl
protein, involved in the negative regulation of the kinase
domain. Bcr-Abl mutants with deleted SH3 induceCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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marrow, but leukemic cell proliferation in vivo is delayed as
a result of reduced tissue invasiveness or leukemogenesis
[9,11,12]. We report the case of a patient initially diagnosed
as CML in chronic phase whose cells expressed the e1a3
variant. This patient readily responded to imatinib 400 mg
with the achievement of a rapid complete cytogenetic re-
sponse and the normalization of the blood count values,
but after 5 months transformed into lymphoid blast crisis.
Case presentation
An 80-year-old Caucasian male sought medical attention
due to 2 months of progressive asthenia, shortness of
the breath, fatigue, and weight loss. The peripheral blood
findings were mild anaemia, haemoglobin 11.8 g/dl, mild
leukocytosis 21 × 109/L with myelocytes 17%, metamye-
locytes 6% and normal platelets. The bone marrow aspir-
ate examination was hypercellular, with bone smear
showing no myeloblasts evidence (or <1% myeloblasts)
and 90% of myeloid cells. A fresh sample from the bone
marrow aspirate was collected for cytogenetic and FISH
analysis. They revealed the presence of a karyotype
46XY, t(9;22) (q34;q11.2) that confirmed the diagnosis of
CML in chronic phase. We highlight that no additional
chromosomal alterations were revealed even after the
evolution to blast crisis. The FISH study was positive for
the BCR/ABL in 50% of interphase cells analyzed. The
patient’s RNA was isolated from the peripheral bloodFigure 1 DNA Sequencing of BCR-ABL e1a3 atypical translocation. We
Besides this band we included the b2a2 (200 bp) and b3a2 (300 bp) BCR-A
transcript this band was extracted from the agarose gel, purified and thenand subjected to a two round multiplex RT-PCR reac-
tion. In order to avoid RNA quality and/or handling er-
rors, we included an internal positive control in which a
690-bp segment of the ubiquitously expressed transcrip-
tion factor E2A mRNA was amplified. The primers and
PCR conditions used in the first and second round of
the nested PCR reaction are described by Pallisgaard
et al. [13]. We identified an atypical amplification band
of approximately 100 bp. In order to confirm the pres-
ence of a BCR-ABL transcript this band was extracted
from the agarose gel, purified and then analyzed by
DNA sequencing. cDNA sequence confirmed the pres-
ence of the e1a3 BCR-ABL transcript (Figure 1). The
initial management with 400 mg/day of Imatinib readily
led to an improvement of clinical and analytical signs
with complete normalization of blood counts. After
3 months a complete BM cytogenetic remission was
achieved. The myelogram showed myeloblasts 2%, pro-
myelocytes 5%, myelocytes 12%, metamyelocytes 36%,
eosinophils 5%, lymphocytes 7% and monocytes 1%.
BM smears were normocellular with discrete erythroid
hypoplasia and no basophilia was observed. Immunophe-
notype studies showed no abnormal cell populations. After
five months of follow up, the patient presented with a
lymphoid blast crisis with 94% of blasts. In BCR-ABL
(e1a3) positive cells cytogenetic analysis revealed no
additional abnormalities apart from the presence of the
Ph- Chromosome. Immunophenotype of the blast cellsobserved an amplification band of approximately 100 bp (e1a3).
BL control bands. In order to confirm the presence of a BCR-ABL
analyzed by DNA sequencing.
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blastic phenotype B: CD19+, CD10+, CD34+, DR+,
CD20 - CD22 -, cytoplasmic IgM negative and positive
alpha CD79. The rest of myeloid and T-cell studied
markers expression were negative (Figure 2).
Discussion
The rare e1a3 translocation has already been reported in
the literature in 3 patients with CML in chronic phase
and in 10 patients with ALL [9,10,13-17]. Surprisingly,
most previously reported cases were detected in ALL pa-
tients and only in a few patients with CML in chronic
phase. This fact together with the benign or indolent
course of the CML with low leukocyte counts could lead
to an underdiagnosed malignancy [9]. Moreover, the diffi-
culties in detecting this atypical translocation with plat-
forms such as GeneXpert could enhance the diagnostic
problems of this type of translocation [9]. We hypothesize
that these e1a3 ALL could represent lymphoid blast crisis
of underdiagnosed e1a3 CML. To our knowledge there are
no myeloid blast crisis described with the e1a3 rearrange-
ment. Deletion of the exon a2 (ABL) from the BCR-ABL
fusion transcript results in a protein that lacks the N-
terminal two thirds of the Src homology 3 (SH3) domainFigure 2 Immnunophenotype of ALL with atypical e1a3 translocation
CD10+, CD34+, DR+, CD20 - CD22 -, cytoplasmic IgM negative and positive[9,16]. Several authors have already indicated that the SH3
domain of the chimeric tyrosine kinase is not necessary for
the activation of intracellular signals regulating proliferation
and survival (RAS, PI-3K, JNK, MAPK, STATs and c-
MYC) of hematopoietic cells but it is essential for full
leukemogenic potential in vivo [11,12]. In this context, and
based on a few cases, the presence of this translocation has
been associated with good outcome of the disease for CML
[9]; there is no such evidence for ALL. However due to the
reduced number of e1a3 CML cases, it is necessary to accu-
mulate more clinical evidences in order to clarify the rela-
tionship between the presence of the e1a3 BCR-ABL
translocation and their clinical course that could be similar
or worse than standard p210 CML as it could confer a
higher risk of transformation to ALL.
Conclusion
This report describes the first case of a CML in chronic
phase with an e1a3 translocation (with a suggested indolent
course), which after 5 months in complete cytogenetic re-
mission transformed into a lymphoid blast crisis. This case
suggests that although imatinib therapy is able of inducing
a very favorable response in the patient does not exempt
them from undergoing to blast crisis. On the other hand,. Presence of a 70% of blasts with lymphoblastic phenotype B: CD19+,
alpha CD79.
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a tendency to progress to a lymphoid blast crisis, some-
times with the chronic phase underdiagnosed.
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